Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).
暂无分享，去创建一个
R. Motzer | T. Powles | M. Atkins | E. Lam | B. Rini | W. Stadler | B. Escudier | S. Oudard | M. Uemura | S. Bracarda | C. Quach | E. Piault | F. Donskov | D. McDermott | C. Suarez | H. Gurney | B. Ding | C. Schiff | C. Grüllich | T. Khaznadar